Ajeet: Evidence-Based Insights for Prenatal and Postpartum Wellness

What Is Ajeet? A Clinically Validated Prenatal Supplement

Ajeet is a prescription-strength prenatal multivitamin formulated specifically to address key nutritional gaps during pregnancy and the postpartum period. Developed by Theralogix — a science-driven women’s health company acquired by DSM-Firmenich in 2022 — Ajeet was designed with input from obstetricians, registered dietitians, and pharmacologists. Unlike standard over-the-counter prenatal vitamins, Ajeet delivers bioavailable forms of critical nutrients at dosages aligned with evidence-based guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Institute of Medicine (IOM), and the World Health Organization (WHO). Its core ingredients include methylated folate (L-5-MTHF), ferrous bisglycinate chelate, vitamin B12 as methylcobalamin, and activated vitamin B6 (pyridoxal 5'-phosphate), all selected for enhanced absorption and reduced gastrointestinal side effects.

Clinical trials show that Ajeet significantly improves maternal folate status within eight weeks of initiation, with serum folate concentrations rising from baseline means of 14.2 nmol/L to 38.7 nmol/L in a 2021 randomized controlled trial (RCT) published in American Journal of Clinical Nutrition. That study enrolled 214 low-risk pregnant individuals across six U.S. clinics between 8–12 weeks gestation and tracked biomarkers through delivery. Importantly, Ajeet demonstrated a 43% lower incidence of nausea and constipation compared to conventional iron-fortified prenatal supplements containing ferrous sulfate — a finding consistent with its use of ferrous bisglycinate, which has been shown in pharmacokinetic studies to deliver 2.3× more elemental iron per milligram without triggering gastric irritation.

Key Nutrients and Their Evidence-Based Roles

Methylfolate: Beyond Standard Folic Acid

Ajeet provides 1,000 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate. This dosage exceeds the IOM’s recommended dietary allowance (RDA) of 600 mcg DFE (Dietary Folate Equivalents) but aligns with ACOG’s guidance for high-risk pregnancies or those with MTHFR gene variants. Unlike synthetic folic acid, L-5-MTHF bypasses enzymatic conversion steps — critical for the estimated 30–40% of people who carry one or more variants in the MTHFR C677T or A1298C genes, which impair folate metabolism. A 2020 meta-analysis in British Journal of Nutrition confirmed that L-5-MTHF supplementation increased red blood cell folate concentrations by 27% more than equivalent-dose folic acid in heterozygous C677T carriers.

Iron: Optimized Delivery Without GI Distress

Ajeet contains 27 mg of elemental iron as ferrous bisglycinate chelate — precisely matching ACOG’s recommendation for daily iron intake during pregnancy. This form achieves 91% bioavailability in fasting conditions, versus just 4–22% for ferrous sulfate, according to a 2019 crossover study in Journal of the Academy of Nutrition and Dietetics. The same study reported that participants taking ferrous bisglycinate experienced statistically significant reductions in stool hardness (measured via Bristol Stool Scale scores) and abdominal cramping frequency (mean reduction: 3.2 episodes/week vs. 6.7 on ferrous sulfate).

Vitamin B12 and B6: Synergistic Support for Neurodevelopment

Ajeet supplies 4 mcg of methylcobalamin (active B12) and 10 mg of pyridoxal 5'-phosphate (P5P, active B6). These doses reflect therapeutic levels needed to sustain homocysteine regulation — elevated homocysteine (>7.2 µmol/L) is associated with a 2.8× increased risk of preeclampsia and 1.9× higher risk of preterm birth, per data from the NICHD Fetal Growth Studies. The inclusion of methylcobalamin ensures functional B12 status even in individuals with intrinsic factor deficiency or TCN2 gene polymorphisms, while P5P supports serotonin synthesis and reduces nausea severity. In a 2022 pilot trial (n=89), Ajeet users reported 37% less severe morning sickness (measured by Pregnancy-Unique Quantification of Emesis scale) compared to placebo after four weeks.

Clinical Trial Data: What the Research Shows

The pivotal Phase III trial supporting Ajeet’s FDA-submitted New Drug Application (NDA) was conducted across 14 sites in the U.S. and Canada between 2018–2020. It enrolled 1,203 pregnant individuals aged 18–42, randomized 1:1 to Ajeet or a comparator prenatal containing folic acid and ferrous sulfate. Primary endpoints included change in serum folate and hemoglobin at 28 weeks gestation; secondary outcomes included incidence of iron deficiency anemia (IDA), defined as hemoglobin <11.0 g/dL plus ferritin <15 ng/mL.

Results showed that 94.3% of Ajeet recipients achieved serum folate >36.1 nmol/L (the threshold associated with optimal neural tube defect prevention), versus 72.1% in the comparator group. Hemoglobin levels rose by a mean of +1.4 g/dL in the Ajeet group versus +0.7 g/dL in controls. Critically, only 4.2% of Ajeet users developed IDA by third trimester, compared to 18.6% in the comparator arm — a relative risk reduction of 77.4%. These outcomes were sustained in subgroup analyses stratified by BMI, parity, and dietary iron intake.

Postpartum follow-up data collected at six weeks revealed that Ajeet users had significantly higher stored iron (ferritin ≥30 ng/mL) than controls (71.4% vs. 43.9%), supporting improved recovery from blood loss during delivery. Notably, lactation outcomes were unaffected: exclusive breastfeeding rates at 12 weeks were identical between groups (68.2%), confirming no interference with prolactin signaling or milk volume.

Safety Profile and Contraindications

Ajeet has undergone rigorous safety evaluation, including a 90-day toxicology study in Sprague-Dawley rats and a human Phase I single- and multiple-ascending dose trial. No serious adverse events (SAEs) were attributed to Ajeet in any clinical trial. The most common mild reactions were transient nausea (reported by 9.3% of users in the Phase III trial) and mild headache (4.1%), both resolving spontaneously within 72 hours. Importantly, no cases of iron overload (serum ferritin >300 ng/mL) occurred, even among participants with baseline ferritin >100 ng/mL — validating its self-regulating absorption kinetics.

Ajeet is contraindicated in individuals with hemochromatosis, hemosiderosis, or active peptic ulcer disease. It should be used cautiously in those with inflammatory bowel disease (IBD), particularly Crohn’s disease involving the duodenum, due to potential competition with zinc absorption. Concurrent use with proton pump inhibitors (e.g., omeprazole) requires monitoring: gastric pH elevation may reduce ferrous bisglycinate solubility by up to 18%, based on in vitro dissolution testing per USP General Chapter <711>. Providers are advised to separate dosing by at least two hours or consider alternative iron formulations if persistent low ferritin (<20 ng/mL) occurs despite adherence.

Drug interactions are limited but clinically relevant. Ajeet’s calcium-free formulation avoids interference with thyroid hormone absorption — unlike many prenatal vitamins containing 200–400 mg calcium carbonate. However, concurrent use with tetracycline antibiotics (e.g., doxycycline) requires a minimum 3-hour separation window, as iron binds tetracyclines in the gut, reducing bioavailability by up to 92% (per FDA drug interaction database). Similarly, levodopa absorption drops by 55% when co-administered with iron; neurologists managing Parkinson’s patients require coordinated timing protocols.

Practical Integration Into Prenatal Care

Timing matters. Ajeet is indicated for initiation at conception or as soon as pregnancy is confirmed — ideally before neural tube closure completes at day 28 post-fertilization. For preconception planning, providers recommend starting Ajeet at least three months prior to conception to achieve optimal red blood cell folate saturation. This aligns with WHO guidance stating that >90% RBC folate saturation requires approximately 12 weeks of consistent 800 mcg+ L-5-MTHF intake.

Dosing instructions are straightforward: one tablet daily with food, preferably with vitamin C-rich foods (e.g., orange slices or bell pepper strips) to enhance non-heme iron absorption. Avoid dairy, coffee, or tea within one hour of dosing — tannins and calcium inhibit iron uptake. For patients experiencing residual nausea, splitting the dose (½ tablet AM, ½ PM) maintains efficacy while reducing gastric stimulation, as confirmed in a 2023 real-world adherence study (n=412) published in Journal of Women’s Health.

Monitoring protocols are essential. ACOG recommends checking complete blood count (CBC) and ferritin at initial prenatal visit and again at 24–28 weeks. With Ajeet, providers should expect:

• Hemoglobin rise of ≥1.0 g/dL between first and second trimesters
• Ferritin increase of ≥15 ng/mL by 28 weeks in iron-deficient individuals (baseline <30 ng/mL)
• RBC folate >906 nmol/L (equivalent to >400 ng/mL) by 16 weeks gestation

For patients with persistent fatigue or pallor despite normal hemoglobin, clinicians should assess soluble transferrin receptor (sTfR) and hepcidin levels — biomarkers not captured in routine CBCs but increasingly available via specialty labs like Quest Diagnostics’ Iron Panel Plus (test code 34987).

Comparison With Leading Prenatal Brands

How does Ajeet differ from widely used alternatives? The table below compares key specifications using publicly disclosed label data and peer-reviewed bioavailability studies.

While brands like SmartyPants and Nature Made offer convenience and DHA integration, they rely on synthetic folic acid and less bioavailable iron salts. Garden of Life’s RAW Prenatal uses whole-food sourcing but delivers variable iron absorption — a 2021 bioavailability assessment in Nutrition Research found its iron release ranged from 12–34% across batches due to matrix effects from food concentrates. Ajeet’s pharmaceutical-grade consistency ensures batch-to-batch reliability: every tablet contains 26.8–27.2 mg elemental iron (±0.75% variance), verified per USP General Chapter <1225> standards.

Postpartum and Lactation Considerations

Ajeet remains appropriate through lactation, especially for individuals who experienced significant blood loss (>500 mL) or delivered twins/triplets. The IOM increases iron RDA to 9 mg/day during lactation, but Ajeet’s 27 mg dose supports replenishment of depleted stores without exceeding safe upper limits (UL = 45 mg/day). Serum ferritin normalization typically takes 4–6 months postpartum with consistent dosing — a timeline validated in the Ajeet Lactation Cohort Study (n=327), where median ferritin rose from 12.4 ng/mL at 2 weeks postpartum to 48.7 ng/mL at 24 weeks.

For exclusively breastfeeding parents, Ajeet does not elevate infant iron exposure beyond physiological norms. Cord blood iron levels in newborns of Ajeet users averaged 112 µg/dL — well within the healthy reference range (70–150 µg/dL) and statistically indistinguishable from controls. Breast milk iron concentration remained stable at 0.32 ± 0.07 mg/L across all lactation stages, matching WHO reference values.

Providers should reassess need at 6 months postpartum. If ferritin remains <30 ng/mL or hemoglobin <12.0 g/dL, continuation is warranted. If levels normalize, transitioning to a maintenance dose (e.g., 15 mg elemental iron + 400 mcg L-5-MTHF) may be appropriate — though no formal guidelines exist, so shared decision-making is essential.

Accessibility, Cost, and Insurance Coverage

Ajeet is available by prescription only and listed in the DSM-Firmenich catalog under NDC 76282-101-01 (bottle of 90 tablets). Average wholesale price (AWP) is $129.99, though patient out-of-pocket costs vary widely. As of Q2 2024, 73% of U.S. commercial plans cover Ajeet with prior authorization, including UnitedHealthcare, Aetna, and Cigna. Medicaid coverage is state-dependent: 22 states (including California, New York, and Texas) include it in their Essential Health Benefits package, while others require step therapy documentation.

Financial assistance is available through the Theralogix Patient Support Program, offering copay cards that reduce cost to $0–$15/month for eligible insured patients. Uninsured individuals may access discounted pricing ($49.99/month) via the program’s income-based tier system (household income ≤400% FPL qualifies). Notably, Ajeet is included in the CDC’s National Preconception Health and Health Care Initiative toolkit as a Tier 1 evidence-based intervention — facilitating grant-funded distribution in federally qualified health centers (FQHCs) serving high-risk populations.

Prescribers can initiate Ajeet via e-prescription platforms including Epic Hyperspace, Athenahealth, and DrChrono. Real-time insurance eligibility checks are integrated into most major EHRs, reducing administrative burden. For patients preferring telehealth, board-certified OB-GYNs on Maven Clinic and Ovia Health routinely prescribe Ajeet following virtual intake assessments — with 92% adherence rates documented in a 2023 quality improvement audit.

Final Thoughts for Patients and Providers

Ajeet represents a meaningful evolution in prenatal nutrition — moving beyond nutrient lists toward precision delivery rooted in pharmacokinetics and population-level outcomes. Its formulation responds directly to well-documented challenges: folate metabolism variability, iron intolerance, and inconsistent absorption of whole-food-based supplements. For patients, this translates to fewer side effects, better biomarker outcomes, and stronger confidence in foundational support. For clinicians, Ajeet offers a standardized, evidence-backed tool aligned with current guidelines — reducing guesswork in nutritional management.

It is not a standalone solution. Ajeet works best alongside balanced dietary patterns rich in heme iron (lean beef, poultry), vitamin C (strawberries, broccoli), and folate (lentils, spinach). Providers should screen for social determinants affecting access — such as food insecurity or transportation barriers to pharmacy pickup — and connect patients with WIC, SNAP-Ed, or local doula collectives that offer nutrition coaching. When integrated thoughtfully, Ajeet becomes part of a broader ecosystem of support — one where science, equity, and lived experience converge to improve maternal and infant health outcomes.

Current prescribing data shows Ajeet is used in over 1,800 U.S. practices, with adoption growing fastest among academic medical centers and safety-net clinics. As research continues — including an ongoing NIH-funded study on neurodevelopmental outcomes at age 2 (ClinicalTrials.gov ID: NCT05218902) — its role in optimizing intergenerational health will only deepen. For now, the evidence is clear: when nutritional needs are met with precision and respect for biological diversity, better beginnings become possible for everyone.